Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Participant is scheduled to undergo elective colon or colorectal surgery by~laparotomy that is scheduled in advance with adequate time prior to surgery to~complete preoperative bowel preparation.~- Participant is a Chinese adult between the ages of more than 18 years old and~less than 81 years old.~- Participant is highly unlikely to conceive.~Exclusion Criteria:~* Participant is undergoing emergency colon or colorectal surgery.~* Participant requires a second planned colorectal surgery or other surgery requiring antibiotic prophylaxis within the 4-week follow-up period.~* Participant is undergoing laparoscopic-assisted surgery.~* Participant is undergoing an isolated rectal procedure.~* Participant has a decompensated intestinal obstruction.~* Participant has active inflammatory bowel disease involving the colon (i.e.,~ulcerative colitis or Crohn's disease).~* Participant is scheduled to undergo an elective colorectal procedure for revision of a previous operation involving a large bowel resection.~* Participant has a bacterial infection at the time of surgery.~* Participant requires or is anticipated to need the administration of other (nonstudy therapy) systemic antimicrobial therapy within 1 week prior to surgery or at any time during this study.~* Participant is anticipated to receive either antibiotic or antiseptic peritoneal lavage during the surgery.~* Participant has a history of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to ertapenem sodium, ceftriaxone sodium, metronidazole, penicillin, or any cephalosporin, beta(β)-lactam, or nitroimidazole agents.~* Participant is breast feeding or plans to breast feed prior to the completion of the study period.~* Participant has neutropenia.~* Participant with immunosuppression due to an underlying disease, chronic~immunosuppressive therapy, or use of high-dose corticosteroids.~* Participant has a rapidly progressive or terminal illness.~* Participant is considered unlikely to survive through the expected 4-week study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ertapenem sodium 1 g (Type: EXPERIMENTAL): Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
- Ceftriaxone sodium 2 g (Type: ACTIVE_COMPARATOR): Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).